EMD Serono

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, EMD Serono sits in the top decile of US sponsors by registered trial count (#303 of 15,742 sponsors by registered trial count).

71 total trials none currently recruiting 48 completed early-phase tilt top decile by trial count

EMD Serono: 71 sponsored US clinical trials, none currently recruiting.

EMD Serono sponsors 71 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 48 completed. 24 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available, with 1 trials.

Top-decile sponsor footprint

EMD Serono ranks in the top decile of sponsors by registered trial count (#303 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 8/100

48 of 71 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (67.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

71 total, page 1 of 2

TERMINATED Phase 2

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

NCT02070978
TERMINATED Phase 1

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

NCT02083679
TERMINATED Phase 4

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

NCT02117050
COMPLETED Phase 4

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

NCT02019550
TERMINATED Phase 3

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

NCT02049151
TERMINATED Phase 2

MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

NCT01973608
COMPLETED Phase 1

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515
COMPLETED Phase 2

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

NCT01972568
COMPLETED Phase 1

Relative Bioavailability of Pimasertib in Cancer Patients

NCT01992874
TERMINATED Phase 2

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

NCT01963611
COMPLETED Phase 2

Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

NCT01936363
TERMINATED

Adherence Trial With MS LifeLines ® Services

NCT01905527
COMPLETED Phase 2

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

NCT01693068
COMPLETED Phase 2

Tecemotide (L-BLP25) in Prostate Cancer

NCT01496131
TERMINATED Phase 1

MSC2015103B in Solid Tumors

NCT01453387
TERMINATED Phase 1

Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

NCT01369628
TERMINATED Phase 1

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

NCT01378377
COMPLETED Phase 1

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT01390818
COMPLETED Phase 2

EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

NCT01360840
TERMINATED Phase 3

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

NCT01237340
TERMINATED Phase 2

Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01226745
COMPLETED

Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)

NCT01207648
COMPLETED Phase 4

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

NCT01085318
TERMINATED Phase 1

First-in-Man, Dose-escalation Trial of c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors

NCT01110083
COMPLETED Phase 4

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial

NCT01034579
COMPLETED Phase 3

A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study

NCT01036165
COMPLETED Phase 2

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01040832
COMPLETED Phase 1

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

NCT01014936
COMPLETED Phase 1

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

NCT01016483
COMPLETED

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials

NCT01013350
COMPLETED Phase 3

The Multicenter, Open-label, Single-use Autoinjector Convenience Study

NCT00958009
TERMINATED Phase 2

Trial of Pimasertib in Hematological Malignancies

NCT00957580
TERMINATED Phase 3

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
COMPLETED Phase 2

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

NCT00813943
TERMINATED Phase 2

Atacicept in Multiple Sclerosis Extension Study, Phase II

NCT00853762
TERMINATED Phase 1

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

NCT00719199
COMPLETED Phase 3

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

NCT00689221
COMPLETED Phase 3

12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.

NCT00735007
COMPLETED

Oocyte Cryopreservation Registry (HOPE Registry)

NCT00699400
TERMINATED Phase 2

Atacicept in Subjects With Optic Neuritis

NCT00624468
TERMINATED Phase 2

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

NCT00642902
COMPLETED Phase 4

Easypod United States User Trial

NCT00689260
COMPLETED Phase 2

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

NCT00624338
TERMINATED Phase 2

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

NCT00573157
COMPLETED

A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment

NCT00702065
COMPLETED Phase 1

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

NCT00633529
COMPLETED Phase 2

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

NCT00595413
COMPLETED Phase 3

Rebif New Formulation (RNF) Quality of Life (QOL) Study

NCT00472797
COMPLETED Phase 3

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

NCT00409188
COMPLETED Phase 2

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

NCT00430495
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 16
Phase 2 24
Phase 3 17
Phase 4 7

Therapeutic Areas

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1
Glioblastoma 1
Glioblastoma Multiforme 1
Multiple Sclerosis 1
Non-Small Cell Lung Cancer 1
Ovarian Cancer 1

How the EMD Serono early-phase archive is shaped

71 indexed studies, none listed as recruiting (0% open); 48 completed (68%).

Phase mix: 24 late (III/IV) vs 40 early (I/II) (early-phase heavy).

Top condition: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

EMD Serono: archived-pipeline peers nationwide

Peers matched on 71 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

EMD Serono sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080 0%5%10%15%20%25% Total trials Recruiting share EMD SeronoCSL BehringNova Southeastern UniversityH. Lundbeck A/SSmith & Nephew10xBio22nd Century Group23andMe3-C Institute for Social Development
EMD Serono sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

EMD Serono sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 71 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this EMD Serono page

71 registered trials is a research-attention snapshot, not an endorsement of EMD Serono or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

EMD Serono pipeline card: 71 registered trials from official public datasets.Report a data error.